NCT00512408

Brief Summary

Background: Patients with congestive heart failure (CHF) show muscle mass wasting and decreased testosterone levels. Long-term testosterone supplementation improves walking distance and glucose metabolism of patients CHF. No studies have investigated the integrated effects of testosterone on exercise oxygen uptake muscle strength and glucose metabolism in patients with CHF regardless of the presence of hypogonadism. Aim: To assess the effect of a 12 week testosterone administration on maximal exercise capacity, muscle strength and insulin resistance in elderly CHF patients. Methods: Seventy elderly patients with stable CHF, mean age 71 ± 8 years, ejection fraction 34 ± 1%, NYHA class II/III 38/32, were enrolled. Of these, 35 were randomized to receive testosterone therapy (through intramuscular injection every 6 week) and 35 to receive placebo both on top of maximal medical therapy. At baseline and after 12 weeks all patients underwent echocardiogram, cardiopulmonary test, 6-minute walking test (6MWT), quadriceps maximal isometric and isokinetic strength.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Jul 2006

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2007

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

August 6, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 7, 2007

Completed
Last Updated

October 17, 2008

Status Verified

August 1, 2007

First QC Date

August 6, 2007

Last Update Submit

October 16, 2008

Conditions

Keywords

To assess the effect of a 12 week testosterone administration on maximal exercise capacity, muscle strength and insulin resistance in elderly CHF patients

Study Arms (2)

A

Drug: testosterone

B

Interventions

Eligibility Criteria

Age56 Years - 76 Years
Sexmale
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • left ventricular ejection fraction (LVEF) \< 40%;
  • New York Heart Association (NYHA) class II or III;
  • clinical stability without hospital admission for heart failure in the previous 3 months.

You may not qualify if:

  • unstable angina or recent acute myocardial infarction,
  • history of severe liver diseases
  • history of severe kidney diseases
  • uncontrolled hypertension
  • erythrocytosis (hematocrit \> 50%)
  • hyperviscosity
  • prostate cancer, prostate-specific antigen (PSA) greater than 3 ng/ml
  • severe lower urinary tract symptoms.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IRCCS San Raffaele

Rome, rome, 00163, Italy

Location

Related Publications (1)

  • Schwartz JB, Volterrani M, Caminiti G, Marazzi G, Fini M, Rosano GM, Iellamo F. Effects of testosterone on the Q-T interval in older men and older women with chronic heart failure. Int J Androl. 2011 Oct;34(5 Pt 2):e415-21. doi: 10.1111/j.1365-2605.2011.01163.x. Epub 2011 May 25.

MeSH Terms

Conditions

Heart Failure

Interventions

Testosterone

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

AndrostenolsAndrostenesAndrostanesSteroidsFused-Ring CompoundsPolycyclic CompoundsTestosterone CongenersGonadal Steroid HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

  • maurizio volterrani, md

    IRCCS san Raffaele Cardiovascular Research Unit

    PRINCIPAL INVESTIGATOR
  • giuseppe marazzi, md

    IRCCS san Raffaele Cardiovascular Research Unit

    PRINCIPAL INVESTIGATOR
  • massaro rosalba, md

    IRCCS san Raffaele Cardiovascular Research Unit

    PRINCIPAL INVESTIGATOR
  • marco miceli

    IRCCS san Raffaele Cardiovascular Research Unit

    PRINCIPAL INVESTIGATOR
  • caterina mammi

    IRCCS san Raffaele Cardiovascular Research Unit

    PRINCIPAL INVESTIGATOR
  • massimo fini, md

    IRCCS san Raffaele Cardiovascular Research Unit

    PRINCIPAL INVESTIGATOR
  • giuseppe rosano, md

    IRCCS san Raffaele Cardiovascular Research Unit

    STUDY DIRECTOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 6, 2007

First Posted

August 7, 2007

Study Start

July 1, 2006

Study Completion

March 1, 2007

Last Updated

October 17, 2008

Record last verified: 2007-08

Locations